C. Maritaz

发表

Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 2, immune checkpoint inhibitor antibodies.

A. Desnoyer, S. Broutin, J. Delahousse, 2020, European journal of cancer.

Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 1, monoclonal antibodies, antibody-drug conjugates and bispecific T-cell engagers.

A. Desnoyer, S. Broutin, J. Delahousse, 2020, European journal of cancer.

Immune checkpoint-targeted antibodies: a room for dose and schedule optimization?

S. Broutin, C. Maritaz, N. Chaput, 2022, Journal of Hematology & Oncology.

Phase II INTERACT-ION study: ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin, and 5-fluorouracil) followed by chemoradiotherapy in patients with Stage III squamous cell anal carcinoma

L. Quéro, C. Maritaz, C. Borg, 2022, Frontiers in Oncology.

High-dose thiotepa-related neurotoxicity and the role of tramadol in children

C. Maritaz, A. Laplanche, A. Laplanche, 2018, BMC Cancer.

Cetuximab-induced aseptic meningitis: case report and review of a rare adverse event

C. Maritaz, G. Deplanque, C. Metz, 2016, BMC Cancer.

Treatment sequence of first and second generation tyrosine kinase inhibitor followed by osimertinib in EGFR-mutated non-small-cell lung cancer: a real life study.

N. Girard, C. Maritaz, D. Moro-Sibilot, 2020, Future oncology.

[Impact of a coordinated regional organization to secure the management of patients on oral anticancer drugs: CHIMORAL, a comparative trial].

F. Tubach, C. Maritaz, J. Lotz, 2019, Bulletin du Cancer.